Diabetes Management Revolution: Combined Drugs Offer Comprehensive Heart and Kidney Protection
![](https://healthwire.co/wp-content/uploads/2024/05/Diabetes-800x600.jpeg)
New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.
Share